Full metadata record
DC FieldValueLanguage
dc.creatorWang, M. (Michael)-
dc.creatorRule, S. (Simon)-
dc.creatorZinzani, P.L. (P. L.)-
dc.creatorGoy, A. (Andre)-
dc.creatorCasasnovas, R. O. (René Olivier)-
dc.creatorSmith, S.D. (Stephen D.)-
dc.creatorDamaj, G. (Gandhi)-
dc.creatorDoorduijn, J.K. (Jeanette K.)-
dc.creatorLamy, T. (Thierry)-
dc.creatorMorschhauser, F. (Franck)-
dc.creatorPanizo, C. (Carlos)-
dc.creatorShah, B. (Bijal)-
dc.creatorDavies, A. (Andrew)-
dc.creatorEek, R. (Richard)-
dc.creatorDupuis, J. (Jehan)-
dc.creatorJacobsen, E. (Eric)-
dc.creatorKate, A.P. (Arnon P.)-
dc.creatorLe-Gouill, S. (Steven)-
dc.creatorOberic, L. (Lucie)-
dc.creatorRobak, T. (Tadeusz)-
dc.creatorJain, P. (Preetesh)-
dc.creatorFrigault, M.M. (Melanie M.)-
dc.creatorRaquel-
dc.creatorNguyen, D. (Dorothy)-
dc.creatorPatel, P (Priti)-
dc.creatorYin, M. (Ming)-
dc.creatorDlugosz-Danecka, M. (Monika)-
dc.date.accessioned2021-12-09T10:44:24Z-
dc.date.available2021-12-09T10:44:24Z-
dc.date.issued2019-
dc.identifier.citationWang, M. (Michael); Rule, S. (Simon); Zinzani, P.L. (P.L.); et al. "Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma". Leukemia. 33, 2019, 2762 - 2766es_ES
dc.identifier.issn0887-6924-
dc.identifier.urihttps://hdl.handle.net/10171/62620-
dc.description.abstractBruton tyrosine kinase (BTK) inhibitors have greatly improved the spectrum of treatment options in mantle cell lymphoma (MCL) [1–4]. Acalabrutinib is a highly selective, orally administered, and potent BTK inhibitor with limited off-target activity [5]. Acalabrutinib was approved in 2017 by the US Food and Drug Administration for the treatment of relapsed/refractory MCL based on clinical data from the open-label, multicenter, phase 2 ACE-LY-004 study of acalabrutinib 100 mg twice daily [1]. Here, we present updated results from the ACE-LY-004 study after a median 26-month follow-up. Eligibility criteria and study design were published previously (Supplementary methods) [1]. Analysis of minimal residual disease (MRD) was conducted after complete response (CR) or partial response (PR) was achieved using the quantitative ClonoSEQ next-generation sequencing (5 × 10−6 ) assay (Adpative Biotechnologies, Seattle, WA, USA) in consenting patients with available paired archival tumor and whole blood samples. Data are updated as of February 12, 2018.es_ES
dc.description.sponsorshipThis study was sponsored by Acerta Pharma, a member of the AstraZeneca Group. We thank the patients who participated in this trial and their families and caregivers; the investigators and coordinators at each study site; and the Acerta Pharma study team, including Sofia Wong. Medical writing assistance was provided by Stephanie Morgan of Team9Science and funded by Acerta Pharma.es_ES
dc.language.isoenges_ES
dc.publisherSpringer Science and Business Media LLCes_ES
dc.rightsinfo:eu-repo/semantics/openAccesses_ES
dc.subjectBruton tyrosine kinase (BTK)es_ES
dc.subjectMantle cell lymphoma (MCL)es_ES
dc.subjectAcalabrutinibes_ES
dc.subjectClinical dataes_ES
dc.titleDurable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphomaes_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.description.noteThis article is licensed under a Creative Commons Attribution 4.0 International Licensees_ES
dc.identifier.doi10.1038/s41375-019-0575-9-
dadun.citation.endingPage2766es_ES
dadun.citation.publicationNameLeukemiaes_ES
dadun.citation.startingPage2762es_ES
dadun.citation.volume33es_ES

Files in This Item:
Thumbnail
File
s41375-019-0575-9.pdf
Description
Size
341.65 kB
Format
Adobe PDF


Statistics and impact
0 citas en
0 citas en

Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.